Article Versions Notes

Cotugno N, Franzese E, Angelino G, Amodio D, Romeo EF, Rea F, Faraci S, Tambucci R, Profeti E, Manno EC, et al. Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens. Vaccines. 2022; 10(7):1109. https://doi.org/10.3390/vaccines10071109

Cotugno, Nicola, Enrica Franzese, Giulia Angelino, Donato Amodio, Erminia Francesca Romeo, Francesca Rea, Simona Faraci, Renato Tambucci, Elisa Profeti, Emma Concetta Manno, and et al. 2022. "Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens" Vaccines 10, no. 7: 1109. https://doi.org/10.3390/vaccines10071109

Cotugno, N., Franzese, E., Angelino, G., Amodio, D., Romeo, E. F., Rea, F., Faraci, S., Tambucci, R., Profeti, E., Manno, E. C., Santilli, V., Rotulo, G. A., Pighi, C., Medri, C., Morrocchi, E., Colagrossi, L., Pascucci, G. R., Valentini, D., Villani, A., ... Palma, P. (2022). Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens. Vaccines, 10(7), 1109. https://doi.org/10.3390/vaccines10071109